IO Biotech (IOBT) Reports 2024 Business Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TFC
8. TRV
9. USB
10. SPY

Go back to IO Biotech (IOBT) Reports 2024 Business Highlights

IO Biotech Reports 2024 Business Highlights

March 4, 2025 4:17 PM EST

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS); the rate of PFS events has slowed and the readout of the primary endpoint is now expected in the third quarter of 2025Enrollment completed ahead of schedule in Phase 2 basket trial of Cylembio as neoadjuvant/adjuvant... More